Skip to main content
Premium Trial:

Request an Annual Quote

Spotfire Signs Deal with MDL, Launches Explorer

Premium

CAMBRIDGE, Mass.--Bioinformatics software developer Spotfire announced last week the release of Spotfire Decision Explorer 1.0, the second in a series of scientific components the company is developing to assist users of its SpotfirePro product with integrating, navigating, and analyzing complex data sets. The Windows-based Decision Explorer automatically generates views that demonstrate complex correlations. The company said features include automatic generation of visualizations based on a target variable, statistical distribution analysis, scoring of variables based on correlations to a targeted result, a decision-tree browser to scan analysis results, and immediate sampling of complex data sets. Results can be used in structure activity analysis, gene expression and preclinical data analysis, and chemical structure and gene expression analysis.

Spotfire CEO Chris Ahlberg said Decision Explorer provides "the advanced functionality at the benchtop to continually guide users along the path to a discovery."

Earlier this month, Spotfire and discovery informatics company MDL Information Systems announced an exclusive joint distribution agreement that granted MDL the right to distribute Spotfire's discovery products--SpotfirePro, Spotfire Structural Visualizer, and Spotfire Discovery Server--to the chemoinformatics segment of the life-science discovery market. Spotfire products will enable MDL customers interactively to integrate, visualize, and analyze data drawn from multiple databases. The companies cooperated previously to develop the Structure Visualizer product, which combines Spotfire Pro's visual discovery and data analysis with MDL's Integrated Scientific Information System chemical structure databases and software.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.